• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小于2岁的小的、I期、组织学良好的威尔姆斯瘤患者的治疗结果:来自国家威尔姆斯瘤研究的报告

Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study.

作者信息

Green D M, Breslow N E, Beckwith J B, Takashima J, Kelalis P, D'Angio G J

机构信息

Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY 14263-0001.

出版信息

J Clin Oncol. 1993 Jan;11(1):91-5. doi: 10.1200/JCO.1993.11.1.91.

DOI:10.1200/JCO.1993.11.1.91
PMID:8380295
Abstract

PURPOSE

Retrospective analyses were performed to determine the effect of tumor weight and therapy modifications on outcome in patients less than 2 years of age with stage I favorable-histology Wilms' tumors.

PATIENTS AND METHODS

The 4-year relapse-free and overall survival percentages for patients randomized to different treatment regimens in National Wilms' Tumor Studies (NWTS)-1, -2, and -3 were calculated and compared.

RESULTS

The 4-year relapse-free survival percentages of patients whose specimen weight was less than 550 g were found to be 89.1% on NWTS-1, 96.0% on NWTS-2, and 93.2% on NWTS-3. There was no evidence that the relapse-free survival of these patients had improved over time (P value for trend = .99). The 4-year relapse-free survival percentage for similar age and stage patients whose specimen weight was 550 g or greater was significantly poorer than that of patients with smaller tumors (P = .02).

CONCLUSION

Changes in the NWTS treatment regimens over a period of more than 20 years have not improved on the excellent prognosis of patients who are less than 2 years of age at diagnosis and who have a stage I, favorable-histology Wilms' tumor with specimen weight less than 550 g. These data could be used as the basis for a future trial in which a subgroup of such patients is treated with nephrectomy only.

摘要

目的

进行回顾性分析,以确定肿瘤重量和治疗方案调整对年龄小于2岁、组织学类型良好的I期威尔姆斯瘤患者预后的影响。

患者与方法

计算并比较在国家威尔姆斯瘤研究(NWTS)-1、-2和-3中随机分配至不同治疗方案的患者的4年无复发生存率和总生存率。

结果

发现标本重量小于550 g的患者在NWTS-1中的4年无复发生存率为89.1%,在NWTS-2中为96.0%,在NWTS-3中为93.2%。没有证据表明这些患者的无复发生存率随时间有所改善(趋势P值 = 0.99)。标本重量为550 g或更大的相似年龄和分期患者的4年无复发生存率明显低于肿瘤较小的患者(P = 0.02)。

结论

在超过20年的时间里,NWTS治疗方案的改变并未改善诊断时年龄小于2岁、患有I期组织学类型良好的威尔姆斯瘤且标本重量小于550 g的患者的良好预后。这些数据可作为未来试验的基础,在此试验中,此类患者的一个亚组仅接受肾切除术治疗。

相似文献

1
Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study.小于2岁的小的、I期、组织学良好的威尔姆斯瘤患者的治疗结果:来自国家威尔姆斯瘤研究的报告
J Clin Oncol. 1993 Jan;11(1):91-5. doi: 10.1200/JCO.1993.11.1.91.
2
Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.间变性组织学肾母细胞瘤的治疗:第五届全国肾母细胞瘤研究结果
J Clin Oncol. 2006 May 20;24(15):2352-8. doi: 10.1200/JCO.2005.04.7852.
3
Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.单侧优势性肾胚胎瘤复发:重要的临床病理因素。
J Pediatr Surg. 2012 Dec;47(12):2210-5. doi: 10.1016/j.jpedsurg.2012.09.010.
4
The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.日本九州地区小儿实体瘤研究组关于初始切除的 Wilms 瘤中胚细胞瘤样组织学为主的预后意义的报告。
J Pediatr Surg. 2012 Dec;47(12):2205-9. doi: 10.1016/j.jpedsurg.2012.09.009.
5
Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group.IV期预后良好组织学类型肾母细胞瘤患儿的治疗:来自国家肾母细胞瘤研究组的报告
Med Pediatr Oncol. 1996 Mar;26(3):147-52. doi: 10.1002/(SICI)1096-911X(199603)26:3<147::AID-MPO1>3.0.CO;2-K.
6
Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group.放线菌素D和阿霉素单剂量与分剂量给药治疗肾母细胞瘤患者的比较:来自国家肾母细胞瘤研究组的报告
J Clin Oncol. 1998 Jan;16(1):237-45. doi: 10.1200/JCO.1998.16.1.237.
7
Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group.非转移性肾母细胞瘤治疗中即刻肾切除术与术前化疗的比较:英国儿童癌症研究组的一项随机试验(UKW3)结果
Eur J Cancer. 2006 Oct;42(15):2554-62. doi: 10.1016/j.ejca.2006.05.026. Epub 2006 Aug 10.
8
Relapse-associated variables in stage I favorable histology Wilms' tumor. A report of the National Wilms' Tumor Study.I期组织学类型良好的肾母细胞瘤的复发相关变量。国家肾母细胞瘤研究报告。
Cancer. 1987 Sep 15;60(6):1204-12. doi: 10.1002/1097-0142(19870915)60:6<1204::aid-cncr2820600608>3.0.co;2-w.
9
Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group.II至IV期间变性肾母细胞瘤患儿的治疗:来自国家肾母细胞瘤研究组的报告
J Clin Oncol. 1994 Oct;12(10):2126-31. doi: 10.1200/JCO.1994.12.10.2126.
10
The treatment of Wilms' tumor patients with pulmonary metastases detected only with computed tomography: a report from the National Wilms' Tumor Study.仅通过计算机断层扫描检测到肺转移的肾母细胞瘤患者的治疗:来自国家肾母细胞瘤研究的报告
J Clin Oncol. 1991 Oct;9(10):1776-81. doi: 10.1200/JCO.1991.9.10.1776.

引用本文的文献

1
Updated favourable-histology Wilms tumour risk stratification: rationale for future Children's Oncology Group clinical trials.更新后的组织学良好型肾母细胞瘤风险分层:儿童肿瘤学组未来临床试验的理论依据
Nat Rev Urol. 2025 Jun 20. doi: 10.1038/s41585-025-01055-1.
2
Inter-Ethnic Variations in the Clinical, Pathological, and Molecular Characteristics of Wilms Tumor.肾母细胞瘤临床、病理及分子特征的种族间差异
Cancers (Basel). 2024 Sep 1;16(17):3051. doi: 10.3390/cancers16173051.
3
Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study.
超过三十年诊断的威尔姆氏肿瘤幸存者的晚期健康结果:来自儿童癌症幸存者研究的报告。
J Clin Oncol. 2023 May 10;41(14):2638-2650. doi: 10.1200/JCO.22.02111. Epub 2023 Jan 24.
4
A 10-Year Study of the Outcome of Wilms' Tumor in Central India and Identifying Practice Gaps.印度中部肾母细胞瘤治疗结果的10年研究及实践差距识别
J Indian Assoc Pediatr Surg. 2022 Jan-Feb;27(1):42-52. doi: 10.4103/jiaps.JIAPS_314_20. Epub 2022 Jan 11.
5
Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature.肾母细胞瘤复发的预后因素:文献综述
Cancers (Basel). 2021 Jun 23;13(13):3142. doi: 10.3390/cancers13133142.
6
Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2.Ⅰ期上皮优势型 Wilms 瘤的预后分析:来自儿童肿瘤协作组 AREN03B2 研究的报告。
Cancer. 2020 Jun 15;126(12):2866-2871. doi: 10.1002/cncr.32855. Epub 2020 Apr 8.
7
Polydatin Encapsulated Poly [Lactic-co-glycolic acid] Nanoformulation Counteract the 7,12-Dimethylbenz[a] Anthracene Mediated Experimental Carcinogenesis through the Inhibition of Cell Proliferation.白藜芦醇苷包裹的聚乳酸-羟基乙酸共聚物纳米制剂通过抑制细胞增殖对抗7,12-二甲基苯并[a]蒽介导的实验性致癌作用。
Antioxidants (Basel). 2019 Sep 5;8(9):375. doi: 10.3390/antiox8090375.
8
Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001.5631 例 Wilms 瘤患儿前瞻性登记于国际小儿肿瘤学会(SIOP)93-01 和 2001 研究中的年龄对预后的意义。
PLoS One. 2019 Aug 19;14(8):e0221373. doi: 10.1371/journal.pone.0221373. eCollection 2019.
9
Pharmacotherapeutic Management of Wilms Tumor: An Update.《威尔姆斯瘤的药物治疗管理:更新》。
Paediatr Drugs. 2019 Feb;21(1):1-13. doi: 10.1007/s40272-018-0323-z.
10
WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk wilms tumors treated with surgery alone: a children's oncology group study.WT1 基因突变和 11p15 杂合性丢失可预测单纯手术治疗的极低危肾母细胞瘤复发:一项儿童肿瘤协作组的研究。
J Clin Oncol. 2011 Feb 20;29(6):698-703. doi: 10.1200/JCO.2010.31.5192. Epub 2010 Dec 28.